Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Long term deficiency of vitamin D in germ cell testicular cancer survivors.

Nappi L, Ottaviano M, Rescigno P, Fazli L, Gleave ME, Damiano V, De Placido S, Palmieri G.

Oncotarget. 2018 Apr 20;9(30):21078-21085. doi: 10.18632/oncotarget.24925. eCollection 2018 Apr 20.

2.

A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness.

di Gennaro A, Damiano V, Brisotto G, Armellin M, Perin T, Zucchetto A, Guardascione M, Spaink HP, Doglioni C, Snaar-Jagalska BE, Santarosa M, Maestro R.

Cell Death Differ. 2018 Apr 17. doi: 10.1038/s41418-018-0103-x. [Epub ahead of print]

PMID:
29666469
3.

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.

Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M, Caruso M, Simonelli M, Perrino M, De Vincenzo F, Toffalorio F, Damiano V, Pasello G, Garbella E, Ali M, Conforti F, Ottaviano M, Cioffi A, De Placido S, Giordano L, Bertossi M, Destro A, Di Tommaso L, Santoro A.

J Clin Oncol. 2018 Feb 1;36(4):342-349. doi: 10.1200/JCO.2017.74.4078. Epub 2017 Dec 14.

PMID:
29240542
4.

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.

Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C, Léna H, Berruti A, Damiano V, Buikhuisen W, Grønbæk H, Lombard-Bohas C, Grohé C, Minotti V, Tiseo M, De Castro J, Reed N, Gislimberti G, Singh N, Stankovic M, Öberg K, Baudin E.

Lancet Oncol. 2017 Dec;18(12):1652-1664. doi: 10.1016/S1470-2045(17)30681-2. Epub 2017 Oct 23.

PMID:
29074099
5.

Predictors of Asymptomatic Radiation-induced Abdominal Atherosclerosis.

Cella L, Liuzzi R, Romanelli P, Conson M, D'Avino V, Ottaviano M, Damiano V, Palmieri G, Pacelli R, Mancini M.

Clin Oncol (R Coll Radiol). 2017 Nov;29(11):e186-e194. doi: 10.1016/j.clon.2017.07.013. Epub 2017 Aug 10.

PMID:
28803687
6.

Evaluation of metabolic response with 18F-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors.

Segreto S, Fonti R, Ottaviano M, Pellegrino S, Pace L, Damiano V, Palmieri G, Del Vecchio S.

Cancer Imaging. 2017 Mar 7;17(1):10. doi: 10.1186/s40644-017-0112-x.

7.

Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1.

Damiano V, Brisotto G, Borgna S, di Gennaro A, Armellin M, Perin T, Guardascione M, Maestro R, Santarosa M.

Genes Chromosomes Cancer. 2017 Feb;56(2):147-158. doi: 10.1002/gcc.22422. Epub 2016 Nov 1.

PMID:
27717206
8.

The future of melanoma therapy: developing new drugs and improving the use of old ones.

Palumbo G, Di Lorenzo G, Ottaviano M, Damiano V.

Future Oncol. 2016 Nov;12(22):2531-2534. doi: 10.2217/fon-2015-0045. Epub 2016 Oct 7. No abstract available.

9.

Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.

Faggiano A, Carratù AC, Guadagno E, Tafuto S, Tatangelo F, Riccardi F, Mocerino C, Palmieri G, Damiano V, Siciliano R, Leo S, Mauro A, Tozzi LF, Battista C, De Rosa G, Colao A.

Oncotarget. 2016 Feb 2;7(5):5538-47. doi: 10.18632/oncotarget.6686.

10.

An improved sequencing-based strategy to estimate locus-specific DNA methylation.

Brisotto G, di Gennaro A, Damiano V, Armellin M, Perin T, Maestro R, Santarosa M.

BMC Cancer. 2015 Sep 21;15:639. doi: 10.1186/s12885-015-1646-6.

11.

Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score.

Faggiano A, Carratù AC, Guadagno E, Tafuto S, Tatangelo F, Riccardi F, Mocerino C, Palmieri G, Damiano V, Siciliano R, Leo S, Mauro A, Tozzi LF, Battista C, De Rosa G, Colao A.

Aliment Pharmacol Ther. 2015 Oct;42(8):1033-4. doi: 10.1111/apt.13381. No abstract available.

12.

Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial.

Palmieri G, Buonerba C, Ottaviano M, Federico P, Calabrese F, Von Arx C, De Maio AP, Marino M, Lalle M, Montella L, Merola C, Milella M, Bergaglio M, Di Lorenzo G, Damiano V.

Future Oncol. 2014 Nov;10(14):2141-7. doi: 10.2217/fon.14.144.

PMID:
25471029
13.

Intracellular inactivation of thyroid hormone is a survival mechanism for muscle stem cell proliferation and lineage progression.

Dentice M, Ambrosio R, Damiano V, Sibilio A, Luongo C, Guardiola O, Yennek S, Zordan P, Minchiotti G, Colao A, Marsili A, Brunelli S, Del Vecchio L, Larsen PR, Tajbakhsh S, Salvatore D.

Cell Metab. 2014 Dec 2;20(6):1038-48. doi: 10.1016/j.cmet.2014.10.009. Epub 2014 Nov 13.

14.

Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.

Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani B, Parsons SJ, De Placido S, Bianco R.

Breast Cancer Res. 2014 May 5;16(3):R45. doi: 10.1186/bcr3650.

15.

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma.

Rosa R, Damiano V, Formisano L, Nappi L, Marciano R, Veneziani BM, De Placido S, Bianco R.

Oncoimmunology. 2013 Aug 1;2(8):e25123. Epub 2013 May 28.

16.

Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.

Rosa R, Damiano V, Nappi L, Formisano L, Massari F, Scarpa A, Martignoni G, Bianco R, Tortora G.

Br J Cancer. 2013 Aug 6;109(3):686-93. doi: 10.1038/bjc.2013.360. Epub 2013 Jul 9.

17.

Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumor.

Moretto R, Cella CA, Raimondo L, Formisano L, Nappi L, Rescigno P, Buonerba C, Calabrese F, Ottaviano M, Di Lorenzo G, Matano E, Damiano V, Palmieri G.

Anticancer Drugs. 2013 Aug;24(7):759-64. doi: 10.1097/CAD.0b013e328362a68b.

PMID:
23695010
18.

Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.

Damiano V, Rosa R, Formisano L, Nappi L, Gelardi T, Marciano R, Cozzolino I, Troncone G, Agrawal S, Veneziani BM, De Placido S, Bianco R, Tortora G.

Br J Cancer. 2013 Apr 30;108(8):1616-23. doi: 10.1038/bjc.2013.153. Epub 2013 Apr 9.

19.

Epigenetic control of type 2 and 3 deiodinases in myogenesis: role of Lysine-specific Demethylase enzyme and FoxO3.

Ambrosio R, Damiano V, Sibilio A, De Stefano MA, Avvedimento VE, Salvatore D, Dentice M.

Nucleic Acids Res. 2013 Apr 1;41(6):3551-62. doi: 10.1093/nar/gkt065. Epub 2013 Feb 8.

20.

Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.

Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R.

Clin Cancer Res. 2013 Jan 1;19(1):138-47. doi: 10.1158/1078-0432.CCR-12-1050. Epub 2012 Nov 19.

21.

Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies.

Palmieri G, Buonerba C, Federico P, Formisano L, Nappi L, Di Lorenzo G, Marino M, Damiano V.

World J Clin Oncol. 2012 Jul 10;3(7):111-5. doi: 10.5306/wjco.v3.i7.111.

22.

Combination of docetaxel and cetuximab for penile cancer: a case report and literature review.

Rescigno P, Matano E, Raimondo L, Mainolfi C, Federico P, Buonerba C, Di Trolio R, D'Aniello C, Damiano V, Palmieri G, De Placido S, Di Lorenzo G.

Anticancer Drugs. 2012 Jun;23(5):573-7. doi: 10.1097/CAD.0b013e328350ead7.

PMID:
22481064
23.

Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.

Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G.

Clin Cancer Res. 2011 Oct 15;17(20):6531-41. doi: 10.1158/1078-0432.CCR-10-3376. Epub 2011 Sep 2.

24.

Imatinib mesylate in thymic epithelial malignancies.

Palmieri G, Marino M, Buonerba C, Federico P, Conti S, Milella M, Petillo L, Evoli A, Lalle M, Ceribelli A, Merola G, Matano E, Sioletic S, De Placido S, Di Lorenzo G, Damiano V.

Cancer Chemother Pharmacol. 2012 Feb;69(2):309-15. doi: 10.1007/s00280-011-1690-0. Epub 2011 Jun 28.

PMID:
21710245
25.

Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials.

Carlomagno C, Daniele G, Bianco R, Marciano R, Damiano V, Matano E, Nappi L, Pepe S, DE Placido S, Tortora G.

Exp Ther Med. 2011 May;2(3):449-455. Epub 2011 Feb 25.

26.

Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report.

Nappi L, Formisano L, Damiano V, Matano E, Bianco R, Tortora G.

Int J Immunopathol Pharmacol. 2010 Oct-Dec;23(4):1281-5.

PMID:
21244780
27.

Is hypogammaglobulinemia a constant feature in Good's syndrome?

Federico P, Imbimbo M, Buonerba C, Damiano V, Marciano R, Serpico D, Di Lorenzo G, Palmieri G.

Int J Immunopathol Pharmacol. 2010 Oct-Dec;23(4):1275-9.

PMID:
21244779
28.

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

Gelardi T, Damiano V, Rosa R, Bianco R, Cozzolino R, Tortora G, Laccetti P, D'Alessio G, De Lorenzo C.

Br J Cancer. 2010 Feb 2;102(3):513-9. doi: 10.1038/sj.bjc.6605499. Epub 2010 Jan 5.

29.

A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action.

Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, Agrawal S, Tortora G.

Clin Cancer Res. 2009 Nov 15;15(22):6921-30. doi: 10.1158/1078-0432.CCR-09-1599. Epub 2009 Nov 10.

30.

Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.

Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R, Albini A, Ryan A, Ciardiello F, Tortora G.

Clin Cancer Res. 2008 Aug 15;14(16):5069-80. doi: 10.1158/1078-0432.CCR-07-4905. Epub 2008 Aug 11.

31.

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs.

Gelardi T, Caputo R, Damiano V, Daniele G, Pepe S, Ciardiello F, Lahn M, Bianco R, Tortora G.

Br J Cancer. 2008 Aug 5;99(3):473-80. doi: 10.1038/sj.bjc.6604493.

32.

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs.

Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F, Tortora G.

Br J Cancer. 2008 Mar 11;98(5):923-30. doi: 10.1038/sj.bjc.6604269. Epub 2008 Mar 4.

33.

Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.

Bianco R, Damiano V, Gelardi T, Daniele G, Ciardiello F, Tortora G.

Curr Pharm Des. 2007;13(33):3358-67. Review.

PMID:
18045190
34.

TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.

Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, Gelardi T, Racioppi L, Fontanini G, De Placido S, Kandimalla ER, Agrawal S, Ciardiello F, Tortora G.

Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12468-73. Epub 2007 Jul 16.

35.

Rational bases for the development of EGFR inhibitors for cancer treatment.

Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G.

Int J Biochem Cell Biol. 2007;39(7-8):1416-31. Epub 2007 May 21. Review.

PMID:
17596994
36.

Purification and characterization of two xylanases from alkalophilic and thermophilic Bacillus licheniformis 77-2.

Damiano VB, Ward R, Gomes E, Alves-Prado HF, Da Silva R.

Appl Biochem Biotechnol. 2006 Spring;129-132:289-302.

PMID:
16915648
37.

Combination of biological therapies in non-small cell lung cancer.

Bianco R, Damiano V, Tortora G.

Ann Oncol. 2006 Mar;17 Suppl 2:ii52-54. Review. No abstract available.

PMID:
16608984
38.

Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.

Damiano V, Caputo R, Bianco R, D'Armiento FP, Leonardi A, De Placido S, Bianco AR, Agrawal S, Ciardiello F, Tortora G.

Clin Cancer Res. 2006 Jan 15;12(2):577-83.

39.

Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

Melisi D, Caputo R, Damiano V, Bianco R, Veneziani BM, Bianco AR, De Placido S, Ciardiello F, Tortora G.

Endocr Relat Cancer. 2005 Dec;12(4):1051-8.

PMID:
16322342
40.

Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.

Damiano V, Melisi D, Bianco C, Raben D, Caputo R, Fontanini G, Bianco R, Ryan A, Bianco AR, De Placido S, Ciardiello F, Tortora G.

Clin Cancer Res. 2005 Aug 1;11(15):5639-44.

41.

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.

De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S, De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G, Bianco AR.

Br J Cancer. 2005 May 9;92(9):1644-9.

42.
43.

Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.

Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco AR, Ciardiello F, Tortora G.

Clin Cancer Res. 2004 Jul 15;10(14):4858-64.

44.

Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments.

Melisi D, Troiani T, Damiano V, Tortora G, Ciardiello F.

Endocr Relat Cancer. 2004 Mar;11(1):51-68. Review.

PMID:
15027885
45.

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G.

Clin Cancer Res. 2004 Jan 15;10(2):784-93.

46.

Effect of Bacillus circulans D1 thermostable xylanase on biobleaching of eucalyptus kraft pulp.

Bocchini DA, Damiano VB, Gomes E, Da Silva R.

Appl Biochem Biotechnol. 2003 Spring;105 -108:393-402.

PMID:
12721462
47.

Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.

Clin Cancer Res. 2003 Apr;9(4):1566-72.

48.

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G.

Clin Cancer Res. 2003 Apr;9(4):1546-56.

49.

Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.

Tortora G, Caputo R, Damiano V, Caputo R, Troiani T, Veneziani BM, De Placido S, Bianco AR, Zangemeister-Wittke U, Ciardiello F.

Clin Cancer Res. 2003 Feb;9(2):866-71.

50.

Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).

Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F.

Clin Cancer Res. 2002 Oct;8(10):3250-8.

Supplemental Content

Loading ...
Support Center